SI2976359T2 - Postopki zdravljenja imperfektne osteogeneze - Google Patents
Postopki zdravljenja imperfektne osteogenezeInfo
- Publication number
- SI2976359T2 SI2976359T2 SI201430985T SI201430985T SI2976359T2 SI 2976359 T2 SI2976359 T2 SI 2976359T2 SI 201430985 T SI201430985 T SI 201430985T SI 201430985 T SI201430985 T SI 201430985T SI 2976359 T2 SI2976359 T2 SI 2976359T2
- Authority
- SI
- Slovenia
- Prior art keywords
- methods
- osteogenesis imperfecta
- treating osteogenesis
- treating
- imperfecta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361803647P | 2013-03-20 | 2013-03-20 | |
| US201361875399P | 2013-09-09 | 2013-09-09 | |
| US201361883151P | 2013-09-26 | 2013-09-26 | |
| EP14717386.8A EP2976359B2 (en) | 2013-03-20 | 2014-03-20 | Methods for treating osteogenesis imperfecta |
| PCT/US2014/031279 WO2014153435A1 (en) | 2013-03-20 | 2014-03-20 | Methods for treating osteogenesis imperfecta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI2976359T1 SI2976359T1 (sl) | 2019-03-29 |
| SI2976359T2 true SI2976359T2 (sl) | 2022-05-31 |
Family
ID=50483613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430985T SI2976359T2 (sl) | 2013-03-20 | 2014-03-20 | Postopki zdravljenja imperfektne osteogeneze |
| SI201431435T SI3312195T1 (sl) | 2013-03-20 | 2014-03-20 | Postopki zdravljenja osteogeneze imperfecta |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201431435T SI3312195T1 (sl) | 2013-03-20 | 2014-03-20 | Postopki zdravljenja osteogeneze imperfecta |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9598486B2 (sl) |
| EP (3) | EP2976359B2 (sl) |
| JP (3) | JP6483086B2 (sl) |
| KR (1) | KR102257138B1 (sl) |
| CN (2) | CN111000997A (sl) |
| AU (1) | AU2014235933B2 (sl) |
| CA (1) | CA2907422C (sl) |
| CL (1) | CL2015002801A1 (sl) |
| DK (2) | DK3312195T3 (sl) |
| EA (1) | EA032327B1 (sl) |
| ES (2) | ES2700238T5 (sl) |
| HK (2) | HK1213576A1 (sl) |
| HR (2) | HRP20181939T4 (sl) |
| HU (1) | HUE046702T2 (sl) |
| IL (2) | IL241461B (sl) |
| LT (2) | LT3312195T (sl) |
| MX (2) | MX369360B (sl) |
| MY (1) | MY172324A (sl) |
| PH (2) | PH12015501864B1 (sl) |
| PL (2) | PL2976359T5 (sl) |
| PT (2) | PT3312195T (sl) |
| RS (2) | RS58188B2 (sl) |
| SG (2) | SG10201701985YA (sl) |
| SI (2) | SI2976359T2 (sl) |
| TW (1) | TWI629995B (sl) |
| UY (1) | UY35493A (sl) |
| WO (1) | WO2014153435A1 (sl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX369360B (es) * | 2013-03-20 | 2019-11-06 | Baylor College Medicine | ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I). |
| WO2018027329A1 (en) * | 2016-08-11 | 2018-02-15 | Precithera, Inc. | TGF-β ANTAGONIST CONJUGATES |
| CN106755395B (zh) * | 2016-12-16 | 2020-05-12 | 山东第一医科大学(山东省医学科学院) | Xi型成骨不全致病基因fkbp10的突变位点及其应用 |
| TWI787230B (zh) * | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI788321B (zh) | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
| WO2018134681A1 (en) * | 2017-01-20 | 2018-07-26 | Sanofi | Anti-tgf-beta antibodies and their use |
| AR110904A1 (es) * | 2017-01-20 | 2019-05-15 | Sanofi Sa | ANTICUERPOS ANTI-TGF-b Y SU USO |
| WO2019113123A1 (en) * | 2017-12-04 | 2019-06-13 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| BR112021000065A2 (pt) | 2018-07-10 | 2021-04-06 | Sanofi | Terapias de combinação contra câncer direcionando cd38 e tgf-beta |
| MX2023004725A (es) * | 2020-10-23 | 2024-02-23 | Hq Han | Antagonistas bifuncionales del factor de necrosis tumoral alfa y del factor de crecimiento transformante beta y usos de los mismos. |
| BR112023022742A2 (pt) * | 2021-05-07 | 2024-01-02 | Baylor College Medicine | Tratamento da osteogênese imperfeita moderada a grave |
| CN113501879B (zh) * | 2021-06-30 | 2022-09-06 | 拜盖特生物科技(上海)有限公司 | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 |
| TW202334209A (zh) * | 2021-11-01 | 2023-09-01 | 美商健臻公司 | 成骨不全症之治療 |
| WO2024149381A1 (en) * | 2023-01-13 | 2024-07-18 | Shanghai Kaijin Biotechnology, Ltd | Multi-specific polypeptide complexes |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6716836A (sl) * | 1967-12-11 | 1969-06-13 | ||
| US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU1525700A (en) * | 1998-11-19 | 2000-06-05 | Board Of Trustees Of The University Of Arkansas, The | Increasing bone strength with selected bisphosphonates |
| US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| ATE338120T2 (de) * | 1998-11-27 | 2006-09-15 | Ucb Sa | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| CA2308532C (en) * | 1999-05-12 | 2005-11-29 | Gador S.A. | Use of bisphosphonates for the treatment of osteogenesis imperfecta |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| HUE042689T2 (hu) * | 2005-02-08 | 2019-07-29 | Genzyme Corp | TGFbéta elleni antitestek |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CA2632799A1 (en) | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| WO2008022182A1 (en) * | 2006-08-16 | 2008-02-21 | The Uab Research Foundation | Methods for promoting coupling between bone formation and resorption |
| TW201934141A (zh) * | 2007-02-09 | 2019-09-01 | 美商艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| CA2683816A1 (en) * | 2007-04-26 | 2008-11-06 | President And Fellows Of Harvard College | Assays for the identification of compounds that modulate bone formation and mineralization |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| BRPI0907220A2 (pt) * | 2008-01-15 | 2019-02-26 | Kalobios Pharmaceuticals, Inc. | métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf |
| JP2012524818A (ja) * | 2009-04-24 | 2012-10-18 | バンダービルト ユニバーシティ | 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法 |
| MX369360B (es) * | 2013-03-20 | 2019-11-06 | Baylor College Medicine | ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I). |
-
2014
- 2014-03-20 MX MX2015013402A patent/MX369360B/es active IP Right Grant
- 2014-03-20 AU AU2014235933A patent/AU2014235933B2/en active Active
- 2014-03-20 SI SI201430985T patent/SI2976359T2/sl unknown
- 2014-03-20 EP EP14717386.8A patent/EP2976359B2/en active Active
- 2014-03-20 LT LTEP17206987.4T patent/LT3312195T/lt unknown
- 2014-03-20 SG SG10201701985YA patent/SG10201701985YA/en unknown
- 2014-03-20 CA CA2907422A patent/CA2907422C/en active Active
- 2014-03-20 UY UY0001035493A patent/UY35493A/es not_active Application Discontinuation
- 2014-03-20 WO PCT/US2014/031279 patent/WO2014153435A1/en active Application Filing
- 2014-03-20 DK DK17206987.4T patent/DK3312195T3/da active
- 2014-03-20 PT PT172069874T patent/PT3312195T/pt unknown
- 2014-03-20 HR HRP20181939TT patent/HRP20181939T4/hr unknown
- 2014-03-20 RS RS20181438A patent/RS58188B2/sr unknown
- 2014-03-20 CN CN201910988588.9A patent/CN111000997A/zh active Pending
- 2014-03-20 CN CN201480028990.8A patent/CN105229028B/zh active Active
- 2014-03-20 PL PL14717386.8T patent/PL2976359T5/pl unknown
- 2014-03-20 SI SI201431435T patent/SI3312195T1/sl unknown
- 2014-03-20 MY MYPI2015702733A patent/MY172324A/en unknown
- 2014-03-20 KR KR1020157028130A patent/KR102257138B1/ko active IP Right Grant
- 2014-03-20 HU HUE17206987A patent/HUE046702T2/hu unknown
- 2014-03-20 PT PT14717386T patent/PT2976359T/pt unknown
- 2014-03-20 TW TW103110468A patent/TWI629995B/zh active
- 2014-03-20 EP EP17206987.4A patent/EP3312195B1/en active Active
- 2014-03-20 ES ES14717386T patent/ES2700238T5/es active Active
- 2014-03-20 SG SG11201506683XA patent/SG11201506683XA/en unknown
- 2014-03-20 ES ES17206987T patent/ES2763869T3/es active Active
- 2014-03-20 DK DK14717386.8T patent/DK2976359T4/da active
- 2014-03-20 EP EP19194235.8A patent/EP3640260A1/en active Pending
- 2014-03-20 JP JP2016504355A patent/JP6483086B2/ja active Active
- 2014-03-20 US US14/772,708 patent/US9598486B2/en active Active
- 2014-03-20 PL PL17206987T patent/PL3312195T3/pl unknown
- 2014-03-20 LT LTEP14717386.8T patent/LT2976359T/lt unknown
- 2014-03-20 RS RS20191624A patent/RS59673B1/sr unknown
- 2014-03-20 EA EA201591843A patent/EA032327B1/ru not_active IP Right Cessation
-
2015
- 2015-08-25 PH PH12015501864A patent/PH12015501864B1/en unknown
- 2015-09-10 IL IL241461A patent/IL241461B/en unknown
- 2015-09-17 CL CL2015002801A patent/CL2015002801A1/es unknown
- 2015-09-18 MX MX2019009122A patent/MX2019009122A/es unknown
-
2016
- 2016-02-11 HK HK16101478.1A patent/HK1213576A1/zh unknown
- 2016-02-11 HK HK18112865.7A patent/HK1253717A1/zh unknown
-
2017
- 2017-02-08 US US15/427,920 patent/US10377819B2/en active Active
-
2019
- 2019-02-06 PH PH12019500261A patent/PH12019500261B1/en unknown
- 2019-02-12 JP JP2019022397A patent/JP6677837B2/ja active Active
- 2019-07-01 US US16/459,023 patent/US11230595B2/en active Active
- 2019-12-17 HR HRP20192277TT patent/HRP20192277T1/hr unknown
-
2020
- 2020-03-12 JP JP2020042524A patent/JP7016113B2/ja active Active
-
2021
- 2021-11-08 IL IL287915A patent/IL287915A/en unknown
- 2021-12-09 US US17/547,069 patent/US20220195025A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287915A (en) | Methods for treating brittle bones | |
| IL240713A0 (en) | Complexes for handling materials | |
| PL2983787T3 (pl) | Sposób leczenia zespołu stresu pourazowego | |
| HK1220155A1 (zh) | 治療癌症的方法 | |
| GB2513368B (en) | Process apparatus | |
| GB201318983D0 (en) | Radiotherapy apparatus | |
| HK1215164A1 (zh) | 處理方法 | |
| AP2015008803A0 (en) | Methods for treating psoriasis using an anti-il-23antibody | |
| HUE042470T2 (hu) | Eljárás széntartalmú anyagok kezelésére gõz termolízissel | |
| ZA201604486B (en) | Timber treatment process | |
| IL245541A0 (en) | New methods for the treatment of neurodegenerative diseases | |
| PT3016682T (pt) | Métodos para tratamento do cancro | |
| EP2941270A4 (en) | METHODS FOR TREATING INFLAMMATION | |
| TWI563128B (en) | Methods for treating aluminum surfaces | |
| GB201302035D0 (en) | UV Apparatus | |
| EP3082251A4 (en) | MOTOR DRIVE DEVICE | |
| GB201322174D0 (en) | Process for treating steel components | |
| ZA201506163B (en) | Methods for treating osteogenesis imperfecta | |
| GB201322764D0 (en) | Treating places | |
| EP2838532A4 (en) | PROCESS FOR TREATING SCLERRODERY |